Peptide "Legalization" and Federal Criminal Exposure: What Florida Compounders, Sellers, and Clinics Need to Know in 2026

Money is pouring into peptides faster than the law is settling. A Bloomberg Businessweek feature this month described the scramble as a gold rush, with importers, telehealth platforms, compounding pharmacies, and wellness clinics all racing to turn a gray market into a legitimate business before the rules are written. Here is the problem for everyone in that race. The FDA has not legalized these peptides. It moved a handful of them one step along a long regulatory path, and the gap between what the headlines say and what the law actually permits is exactly where federal criminal cases get built.

The FDA has not legalized peptides. It removed a handful from a Category 2 restriction list. That is a different thing, and the gap between those two facts is where federal criminal exposure lives.

What the FDA Actually Did, and What It Did Not Do

In late 2023 the FDA placed nineteen widely used peptides on its 503A Category 2 list, the designation reserved for substances flagged for significant safety concerns. That move effectively barred compounding pharmacies from preparing them. In February 2026 HHS signaled it wanted to ease those restrictions. On April 15, 2026, the FDA announced it would remove twelve of those peptides from Category 2 after seven days, because the nominations supporting their restriction had been withdrawn. The next day it published a Federal Register notice scheduling a public advisory-committee meeting.

The seven peptides on the July 2026 agenda are BPC-157, KPV, TB-500, and MOTs-C on day one, and Emideltide (DSIP), Semax, and Epitalon on day two. Five more are slated for review before the end of February 2027.

Coming off Category 2, getting onto the 503A bulks list, and earning FDA drug approval are three different things. The agency said plainly that removal from Category 2 does not, on its own, authorize compounding or bring a substance within the interim enforcement-discretion policy that applies to Category 1. These peptides sit in a gray zone. They are no longer flagged as high-risk, but they are not cleared either. "Legal again" is a headline, not the law.

Coming off Category 2 is not FDA approval. It is not authorization to compound. It is not a safe harbor. The agency said so directly in its April 2026 notice, and federal prosecutors are reading the same document.

Where the Government Is Concentrating Its Attention

The enforcers here are the FDA Office of Criminal Investigations and the Justice Department, often the Consumer Protection Branch working with a U.S. Attorney's Office. Their attention concentrates on importers and distributors selling vials directly to the public, e-commerce operators with influencer marketing budgets, telehealth platforms that cut corners on the prescriber relationship, and compounders who got ahead of final FDA action.

The phrase "research use only" or "not for human consumption" on a label is not the shield people think it is. Prosecutors read that disclaimer the opposite way. They treat it as evidence the seller understood the product was headed into someone's body and papered the file to look otherwise. When the marketing, the dosing guidance, and the customer base all point at human use, the label becomes proof of intent, not a defense to it.

Supply chain matters too. A great deal of raw peptide material is sourced overseas. The moment a product crosses the border outside lawful channels, the case is no longer just about a drug. It becomes a customs and importation case, and can pull in the Drug Supply Chain Security Act, 21 U.S.C. section 360eee.

A research-use-only label does not limit what the government can charge. It is evidence that the seller knew the product was headed into someone's body and chose to label it otherwise. That reading helps prosecutors, not defendants.

The Federal Charges That Actually Come Out of This

Most peptide cases are built on the Food, Drug, and Cosmetic Act. The core prohibited acts live in 21 U.S.C. section 352 for misbranding and 21 U.S.C. section 355 for introducing an unapproved new drug into interstate commerce, enforced through 21 U.S.C. section 331. The penalty section, 21 U.S.C. section 333, has two tiers. A straight FDCA violation is a misdemeanor on a strict-liability theory: no bad intent required. Add intent to defraud or mislead and it becomes a felony carrying up to three years per count.

That is rarely where prosecutors stop. The felony fraud theory opens the door to wire fraud (up to 20 years), smuggling under 18 U.S.C. section 545 (up to 20 years), conspiracy under 18 U.S.C. section 371, and money laundering attaches to the proceeds. Where a clinic actually bills, you can add health care fraud under 18 U.S.C. section 1347, the Anti-Kickback Statute, and civil False Claims Act liability.

Sentencing turns on loss amount or the volume of product moved, with enhancements for sophistication, leadership role, and number of victims.

A grand jury subpoena is not an opening negotiation. By the time it arrives, the investigation is already built. The records it demands will shape every charging decision that follows.

The Mistakes That Turn a Regulatory Problem Into an Indictment

Treating an FDA warning letter as the end of the story rather than the opening move. Talking to OCI agents without counsel in the room. Producing customer lists, supplier records, and emails in response to a grand jury subpoena with no strategy and no privilege review. Believing the April 2026 reclassification made past sales legal, when it did nothing of the kind and is not retroactive. Assuming research-use-only labeling is a defense.

And the most common one: waiting for the indictment to hire a lawyer, by which point most of the leverage is already gone.

How These Cases Are Actually Defended

Pre-indictment defense is where FDCA and compounded-drug cases are won or lost. Early intervention lets counsel engage the agents and the prosecutor through a single controlled channel, respond to a target letter on the client's terms, and shape the narrative before a charging decision hardens.

Intent is the center of gravity. Because 21 U.S.C. section 333 splits a misdemeanor from a felony on the question of intent to defraud or mislead, the defense lives or dies on whether the conduct reads as a compliance failure or a scheme. A client who ran a licensed 503A or 503B pharmacy in good-faith reliance on shifting FDA guidance has a real argument against the felony intent element, and that argument is far stronger when a lawyer is making it during the investigation than after an indictment is returned.

"The argument that a licensed pharmacy relied in good faith on shifting FDA guidance is real. But it has to be made during the investigation, not after charges are filed."— Aaron M. Cohen, Principal Attorney

Why the Next Month Matters

The advisory committee meets on July 23 and 24, 2026, and the gold rush is accelerating into that date. A favorable vote would give licensed compounding pharmacies a lawful 503A pathway to prepare these peptides with a valid prescription. It would not legalize research peptide sales to the public, would not turn these into FDA-approved drugs, and would not erase anything that already happened.

The charging decisions being weighed right now are about conduct during the gray-area period: the years when the rules were unsettled and the sales were brisk. Anyone who scaled a peptide operation between 2024 and 2026 is squarely inside the window where the government is still deciding whom to charge. The forward-looking rule change does not close that window.

AMC Defense Law represents pharmacies, clinics, telehealth operators, importers, and individuals in federal investigations and prosecutions in the Southern District of Florida and nationwide. The work that matters most happens before charges are filed.

AMC Defense Law defends pharmacies, clinics, telehealth operators, and importers in federal peptide and compounded-drug investigations in the Southern District of Florida and nationwide.

If you are operating in the peptide or compounding space and have questions about your criminal exposure, call Aaron M. Cohen, 24 hours a day.

This article is for informational purposes only and does not constitute legal advice. No attorney-client relationship is formed by reading this content.